Bharat Biotech seeks DCGI nod for nasal vax trials

Days after getting the Drugs Controller General of India’s (DCGI) nod for India’s first indigenously made COVID-19 vaccine, Bharat Biotech has once more knocked on the doorways of the drug controller searching for permission to conduct medical trials of their intranasal vaccine for the viral illness. Hyderabad-based Bharat Biotech has utilized to the DGCI for permission to begin Phase 1 and a pair of trials of their nasal coronavirus vaccine, prime sources aware about the event informed IANS. Also Read – Commonly used blood strain drugs protected for COVID-19 sufferers


As the identify suggests, a nasal vaccine is run through the nostril. This is a non-invasive and painless methodology of vaccine supply because it doesn’t require a needle. This sort of vaccine induces immunity by means of the internal floor of the nostril, which is the place that’s uncovered to airborne microbes. Here is what we all know concerning the nasal vaccine. Also Read – Initial COVID-19 severity could not up later respiratory issues

Nasal vaccine to be a single dose one

Clinical trials of the ‘BBV154’ – a novel adenovirus vectored, intranasal vaccine for coronavirus — shall be carried out at varied areas. The vaccine shall be a single-dose one. According to the agency, an intranasal vaccine stimulates a broad immune response on the web site of an infection, within the nasal mucosa, which is crucial for blocking each an infection and transmission of COVID-19. Also Read – Alarmingly excessive vitamin D deficiency could make you extra susceptible to COVID-19: Study

A non-invasive various

The nasal vaccine is totally different from the 2 intramuscular vaccines which lately received approval, as a consequence of being non-invasive, needle-free, not requiring educated healthcare staff, eliminating needle-associated dangers, and appropriate for youngsters and adults, having scalable manufacturing.

More efficient than intramuscular immunisations

The vaccine has demonstrated protecting efficacy in mice and hamsters. Mice and hamsters immunised with its single dose conferred superior safety in opposition to SARS-CoV-2 problem, “more so than one or two intramuscular immunisations of the same vaccine and dose”.

It creates an immune response within the nostril

Intranasal immunisation of ChAd-SARS-CoV-2-S can create an immune response within the nostril, which is the purpose of entry for the virus, thereby defending in opposition to illness, an infection and transmission,” Bharat Biotech stated in an announcement.


On January 3, two intramuscular vaccines – Bharat Biotech’s Covaxin and Oxford-AstraZeneca’s Covishield manufactured by Serum Institute of India – had been authorised for restricted emergency use. Both are two-dose vaccines. While the total efficacy of Covaxin is but to be decided, it was given the go-ahead by the DCGI citing ‘public interest’. Covaxin is an indigenously developed vaccine by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).

(With inputs from IANS)

Published : January 9, 2021 8:00 am | Updated:January 9, 2021 8:01 am


Back to top button